Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
Sponsor: Kamada, Ltd.
A PHASE3 clinical study on Rabies, this trial is completed. The trial is conducted by Kamada, Ltd. and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Mar 2019 — Jan 2021 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kamada, Ltd.
- Kedrion S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .